- Joint research initiated with the University of Perugia, Italy
- Securing a foothold in the global premium market following successful canine skin regeneration cases in Korea

ROKIT Healthcare (KOSDAQ: 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, is expanding its reach into the global bio-animal organ regeneration market by entering the premium European racehorse regenerative medicine sector.

The company has announced a collaborative research project with the Department of Veterinary Medicine at the University of Perugia, Italy, and leading European medical device companies. This initiative marks the world’s first joint research effort to utilize AI and organ regeneration platform technology for the regeneration of skin and cartilage in racehorses.

■ "Making the Impossible Possible": Combining AI, 3D Bioprinting, and Regenerative Medicine

The core of this project lies in transitioning the treatment of intractable skin and cartilage damage in racehorses—previously considered incurable by conventional veterinary methods—into the realm of "regenerable" conditions.

ROKIT Healthcare’s platform utilizes AI-based precision tissue design and 3D bioprinting to provide customized treatments that restore the complex tissue structures of horses (Equine) to near-perfection. This project is garnering industry attention as the world’s first animal regeneration platform capable of immediate commercialization beyond mere research.

Before its full-scale entry into the European racehorse market, ROKIT Healthcare secured the trust of the European veterinary community by confirming the technical efficacy of its platform in the field of pet skin regeneration in Korea. According to a study published in the veterinary journal E-JVC (Journal of Veterinary Clinics), the use of ROKIT’s organ regeneration platform on intractable canine skin lesions resulted in 100% regeneration of skin and hair within 25 days. This case proved that the technology offers significantly superior regeneration speed and tissue restoration compared to existing treatments.

■ Targeting the $10.4 Billion ‘High-Value Asset Protection’ Industry

A key feature of this expansion is the application of technologies originally developed for human organ regeneration to the equine sector. The racehorse market is categorized not just as animal healthcare, but as a high-value asset protection industry. According to Grand View Research, the demand for regenerative therapies in the racehorse healthcare market is estimated to grow to approximately $10.4 billion (approx. 15 trillion KRW) by 2033.

There are approximately 700,000 racehorses and sport horses in Europe eligible for treatment. Despite treatment costs often reaching tens of thousands of dollars per session, there is strong demand from owners to maintain performance and preserve the asset value of the horses. Furthermore, because horses share high biological similarity with humans and veterinary clinical regulations are relatively flexible, it is a high-profit market where investment efficiency is realized immediately based on treatment outcomes.

"This entry into the European racehorse regeneration market is a major milestone that completes our three-axis strategy: AI, Organ Regeneration Platform, and Global Verification," stated an official from ROKIT Healthcare. "We intend to solidify our position as a regenerative medicine platform that goes beyond human AI organ regeneration to innovate the quality of life for animals as well."